人工耳蜗翻修植入伴装置制造商更换:手术结果与言语感知表现
该回顾性病例回顾纳入1989至2020年185例人工耳蜗翻修植入,其中39例(21%)涉及制造商更换。更换组医疗指征比例(31% vs 11.5%,P=.007)、症状出现至翻修间隔(43 vs 20.3个月,P=.001)及同耳多次翻修率(25.6% vs 8.2%,P=.009)均高于未更换组。多数病例言语感知改善或不变(84%),两组间无显著差异(P=.183),未报告并发症。
要点
- 185例翻修中39例(21%)涉及制造商更换,多为儿童患者(67%)。
- 更换组医疗指征比例更高(31% vs 11.5%,P=.007),翻修间隔更长(43 vs 20.3个月,P=.001)。
- 两组完全再插入率高(94.8% vs 94.5%,P=1),言语感知多数改善或不变(84%),组间无显著差异(P=.183)。
核心结论
- 涉及制造商更换的人工耳蜗翻修植入安全且有益,制造商更换未影响手术或言语感知结果。
研究设计与样本
- 回顾性病例回顾,三级学术中心,纳入1989至2020年全部人工耳蜗翻修植入共185例。
主要发现
- 185例翻修中39例(21%)涉及制造商更换,其中儿童患者占67%。
- 更换组医疗指征比例为31%,未更换组为11.5%(P=.007),更换组约为未更换组的3倍。
- 症状出现至翻修间隔更换组为43个月,未更换组为20.3个月(P=.001)。
- 同耳多次翻修率更换组为25.6%,未更换组为8.2%(P=.009)。
- 完全再插入率更换组为94.8%,未更换组为94.5%(P=1),未报告并发症;言语感知改善或不变者占84%,两组间无显著差异(P=.183)。
临床怎么用
- 作者认为,本研究为循证数据,可支持人工耳蜗团队和患者进行知情决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Describe the clinical profile of revision cochlear implantation (RCI) cases involving device manufacturer conversion (RCImc+), compare them to cases without manufacturer conversion (RCImc-), and classify the reasons for manufacturer conversion (MC). STUDY DESIGN: Retrospective case review. SETTING: Tertiary academic center. METHODS: Data on demographics, RCI indications, medical background, surgical details, and the reasons for MC were collected for all RCIs from 1989 to 2020. Post-RCI speech perception performance was categorized as unchanged, improved, or declined, according to clinically based criteria. RESULTS: Of 185 RCIs, 39 (21%) involved MC, mostly in pediatric patients (67%). The leading RCImc+ indications were device-related (59%) and medical (31%) failures. Initial implant manufacturers were Advanced Bionics (49%), Cochlear (25.5%), or Medel (25.5%). Most MC reasons were patient-driven (64%) versus CI team recommendations (36%). The RCImc+ group demonstrated a 3-fold higher rate of medical indications than RCImc- (31% vs 11.5%, P = .007). The time interval from symptom onset to RCI was longer in RCImc+ (43 vs 20.3 months, P = .001), and the rate of multiple revisions in the same ear was higher (25.6% vs 8.2%, P = .009). Complete reinsertion rates were high in both RCImc+ and RCImc- (94.8% vs 94.5%, P = 1) without any complications. Speech perception improved or remained unchanged in most (84%) cases, with no significant difference between the groups (P = .183). CONCLUSION: This retrospective study showed that RCI involving MC is safe and beneficial. Although RCImc+ patients exhibited distinct clinical characteristics, MC did not impact surgical or speech perception outcomes. This provides evidence-based data to support informed decision-making by CI teams and patients.
引用
- Yaar-Soffer Y, Shapira Y, Sagiv D, et al. Revision Cochlear Implantation With Device Manufacturer Conversion: Surgical Outcomes and Speech Perception Performance. Otolaryngol Head Neck Surg. 2024. PMID: 38716795. doi:10.1002/ohn.805
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。